Background: Alzheimer's disease (AD) is neurodegenerative disease brought on by a combination of changes in multiple pathways that conglomerate to promote disease progression. AD often occurs alongside comorbid diseases, most often immune or vascular in nature, which have been shown to further increase AD risk. We previously showed that known AD variants also associate with secondary diseases in these categories, including rheumatoid arthritis, ischemic myocardial infarction, and both Type 1 and Type 2 diabetes. To better understand which pathways play a significant role in AD etiology and how comorbid diseases may contribute to risk through shared pathways, we aimed to identify gene expression changes associated with AD status in tissues throughout the body.

Method: We conducted a transcriptome-wide association study (TWAS) using genotypes from the Alzheimer's Disease Sequencing Project (ADSP) including 11,074 cases and 14,310 controls from multiple ancestry groups and reference expression-trait quantitative loci (eQTLs) from 49 tissues in Genotype-Tissue Expression (GTEx) Project (v8). Using an ensemble approach we first predicted genetically regulated gene expression (GREx) and gene-associations per tissue within each of the 49 tissues available in GTEx using PrediXcan. Secondly, to better predict cross-tissue signals we used MulTiXcan with GREx to test for gene-associations across tissues.

Result: Both known and novel genes appeared in the single tissue and cross tissue gene associations. Previously AD-associated genes PET117, RAB35, NECTIN2, APOC1, and TOMM40 were significantly associated (p<1.51e-7) with AD across tissues, with many of these known to lie within the APOE region. Additionally, genes previously unreported with AD, but involved in relevant disease processes including macro-autophagy (SUPT20H), nucleosome binding (HMGN2), histone acetylation (KAT14), DNA damage repair (HFM1), and immune response (TSPAN2) showed significance. Many of these novel genes have previously been associated with immune, vascular and other neurological diseases, many of which are better known to appear as AD comorbidities.

Conclusion: In addition to known APOE region genes, novel genes with implications relevant to AD etiology and ties to other immune, vascular, and neurological diseases also appeared significant across tissues. Next we will investigate how these gene expression changes apply to pathways within relevant tissues.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.087088DOI Listing

Publication Analysis

Top Keywords

alzheimer's disease
8
comorbid diseases
8
gene expression
8
basic science
4
science pathogenesis
4
pathogenesis background
4
background alzheimer's
4
disease
4
disease neurodegenerative
4
neurodegenerative disease
4

Similar Publications

β-secretase (BACE1) is instrumental in amyloid-β (Aβ) production, with overexpression noted in Alzheimer's disease (AD) neuropathology. The interaction of Aβ with the receptor for advanced glycation endproducts (RAGE) facilitates cerebral uptake of Aβ and exacerbates its neurotoxicity and neuroinflammation, further augmenting BACE1 expression. Given the limitations of previous BACE1 inhibition efforts, the study explores reducing BACE1 expression to mitigate AD pathology.

View Article and Find Full Text PDF

Dementia refers to an umbrella phenotype of many different underlying pathologies with Alzheimer's disease (AD) being the most common type. Neuropathological examination remains the gold standard for accurate AD diagnosis, however, most that we know about AD genetics is based on Genome-Wide Association Studies (GWAS) of clinically defined AD. Such studies have identified multiple AD susceptibility variants with a significant portion of the heritability unexplained and highlighting the phenotypic and genetic heterogeneity of the clinically defined entity.

View Article and Find Full Text PDF

Amyloidogenic protein aggregation is a pathological hallmark of Alzheimer's Disease (AD). As such, this critical feature of the disease has been instrumental in guiding research on the mechanistic basis of disease, diagnostic biomarkers and preventative and therapeutic treatments. Here we review identified molecular triggers and modulators of aggregation for two of the proteins associated with AD: amyloid beta and tau.

View Article and Find Full Text PDF

Background: Certain peripheral proteins are believed to be involved in the development of Alzheimer's disease (AD), but the roles of other new protein biomarkers are still unclear. Current treatments aim to manage symptoms, but they are not effective in stopping the progression of the disease. New drug targets are needed to prevent Alzheimer's disease.

View Article and Find Full Text PDF

The Trail of axonal protein Synthesis: Origins and current functional Landscapes.

Neuroscience

January 2025

Departamento de Genómica, Instituto de Investigaciones Biológicas Clemente Estable, MEC, Av. Italia 3318, Montevideo, CP 11600, Uruguay; Departamento de Biología Celular y Molecular, Facultad de Ciencias, Universidad de la República, Iguá, Montevideo, 4225, CP 11400, Uruguay. Electronic address:

Local protein synthesis (LPS) in axons is now recognized as a physiological process, participating both in the maintenance of axonal function and diverse plastic phenomena. In the last decades of the 20th century, the existence and function of axonal LPS were topics of significant debate. Very early, axonal LPS was thought not to occur at all and was later accepted to play roles only during development or in response to specific conditions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!